3//SEC Filing
TPAV, LLC 3
Accession 0000929638-24-001346
CIK 0001130598other
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 7:51 PM ET
Size
6.0 KB
Accession
0000929638-24-001346
Insider Transaction Report
Form 3
TPAV, LLC
10% Owner
Holdings
Series C Preferred Stock
→ Common Stock (25,843,663 underlying)- 885,532
Common Stock
Footnotes (2)
- [F1]Received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in connection with the acquisition (the "Merger") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd. Upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of common stock of the Company, par value $0.01 per share ("Common Stock"), on a 1:20.1291 basis pursuant to the terms of the Merger Agreement.
- [F2]Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.
Documents
Issuer
Traws Pharma, Inc.
CIK 0001130598
Entity typeother
IncorporatedNV
Related Parties
1- filerCIK 0002017798
Filing Metadata
- Form type
- 3
- Filed
- Apr 2, 8:00 PM ET
- Accepted
- Apr 3, 7:51 PM ET
- Size
- 6.0 KB